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Abstract
The normally soluble TAR DNA Binding Protein 43 (TDP-43) is found aggregated both in 
reversible stress granules and irreversible pathogenic amyloid. In TDP-43, the low complexity 
domain (LCD) is believed to be involved in both types of aggregation. To discover the structural 
origins of these two modes of β-sheet rich aggregation, we have determined ten structures of 
segments of the LCD of human TDP-43. Six of these segments form steric zippers characteristic 
of the spines of pathogenic amyloid fibrils; four others form LARKS, the labile amyloid-like 
interactions characteristic of protein hydrogels and proteins found in membrane-less organelles, 
including stress granules. Supporting a hypothetical pathway from reversible to irreversible 
amyloid aggregation, we found that familial ALS variants of TDP-43 convert LARKS to 
irreversible aggregates. Our structures suggest how TDP-43 adopts both reversible and irreversible 
β-sheet aggregates, and the role of mutation in the possible transition of reversible to irreversible 
pathogenic aggregation.
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Introduction
The role of low complexity domains (LCDs) in proteins linked to neurodegenerative 
diseases is a topic of intense current investigation1–3. LCDs are regions of proteins that 
exhibit biased compositions of amino acids and frequently no secondary structure4–6. In 
some cases the LCDs are the result of nucleotide expansions that cause duplications of short 
sequences, as in Huntington’s Disease7. In other cases the LCDs are intrinsic to the protein 
and believed to have a functional role as in the RNA binding proteins TAR DNA binding 
protein 43 (TDP-43), Fused in sarcoma (FUS) and hnRNPA18, whose LCDs participate in 
formation of stress granules1,9,10.
Stress granules (SGs) are aggregates of RNA and RNA binding proteins that form in the 
cytoplasm when the cell experiences physical, mechanical or chemical stress11,12. This 
process is often initiated by a halt in translation and puts the cell in a hibernating state until 
the stress subsides13. SGs are reversible, meaning that SG-proteins disaggregate when the 
stress is relieved, the disaggregated proteins and RNA are then free to return to their normal 
functions in the cell1,2,14,15. Phosphorylation has been shown to play a role in these SG-
proteins dynamics16,17. Over the last decade, researchers have studied how this process 
occurs and what biophysical properties these aggregates exhibit. Recent studies on G3BP-1, 
a SG protein, have demonstrated that the SGs exist in a biphasic state with the mRNA 
packed at the center and the RNA-binding proteins on the periphery18. Also, foci composed 
entirely of RNA have been observed as a product of phase transition in human cells19. The 
mechanism of SGs assembly and the role of RNA are still being investigated1,3,15,20. Studies 
on FUS and hnRNPA1 have demonstrated that the LCDs are sufficient for liquid-liquid 
phase separation (LLPS)1,15. Despite progress, questions remain about the structures of the 
aggregates and how these may differ between SG assemblies and pathogenic states4.
Our recent study determined atomic structures of five segments of low-complexity domains 
of FUS, hnRNPA1, and nup9821. All of these displayed kinked β-sheets with weak 
interactions between sheets. We gave these structures the acronym LARKS (Low-
complexity Aromatic-Rich Kinked Segments), and proposed that these LARKS act as Velcro 
to provide adhesion between LCDs to form SGs or other membrane-less organelle 
assemblies. These structures contrast with steric-zippers which act as molecular glue to 
fasten together amyloidogenic segments in amyloid fibrils(reviewed in22). Our study of 
LARKS offered an atomic-resolution hypothesis about the molecular mechanism of SG 
formation.
In addition to studies aimed at determining the structure of SG assemblies, researchers have 
focused on the role of SG-associated proteins in neurodegenerative diseases. One of the 
major hallmarks of neurodegenerative diseases is the deposition of proteinaceous amyloid 
fibrils in cells23. Different from SG assembly, aggregation of proteins into the amyloid state 
in disease seems a virtually irreversible process22,24. Variants found in TDP-43, FUS and 
hnRNPA-1 have all been linked to Amyotrophic Lateral Sclerosis (ALS) among other 
diseases25.
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TAR DNA Binding Protein (TDP-43) is a 43kD protein composed of four domains: an N-
terminal domain, two RNA recognition domains and a C-terminal low complexity domain 
(LCD)26–28. This protein is involved in a number of cellular functions including mRNA 
shuttling, transcription, miRNA processing and alternative splicing among others29,30. Over 
the past decade, research into TDP-43 has found aggregates of the protein in patients with 
ALS, Alzheimer’s Disease, Parkinson’s Disease, Frontotemporal Lobar Degeneration and 
Huntington’s Disease31–34. These aggregates are irreversible, ubiquitinated, hyper-
phosphorylated, C-terminal cleavage products ranging in size from 25–35kD35. Thus it is 
hypothesized that the LCD of TDP-43 plays a role in both this irreversible disease 
aggregation and reversible SG aggregation.
Of proteins that participate in SGs and also form pathogenic amyloid fibrils, TDP-43 stands 
out for four reasons. First, TDP-43 has over 45 variants that are linked to ALS and other 
neurodegenerative diseases25,36,37. Second, the majority of the variants that cause disease 
are localized to the LCD38,39. Third, the majority of the aggregates found in the cytoplasm 
of cells of patients are cleavage products inclusive of the LCD40,41. Finally, TDP-43 is found 
to aggregate in 97% of sporadic cases and 45% of familial case of ALS42,43. This makes 
TDP-43 an intriguing candidate for understanding how its LCD participates in both 
reversible SG assembly and irreversible, pathogenic assembly.
Through structure determination, we can learn which segments of TDP-43 may drive 
aggregation and how familial variants affect this process. Here we use x-ray diffraction and 
micro-electron diffraction (MicroED) to determine the atomic resolution structures of ten 
peptide segments, seven in the reference sequence and three variants, from the LCD of 
TDP-43. We show that the LCD is capable of forming typical steric-zipper β-sheet structures 
characteristic of pathogenic aggregation. Also we show that segment 312–317 forms a 
kinked, labile structure—a LARKS, predicted as a protein interaction motif consistent with 
properties of SG assemblies21. We also show how this structure is perturbed by the familial 
mutants A315T and A315E, which provides an opportunity for understanding the interplay 
of formation of membrane-less organelles with pathogenic amyloid.
Results
Six segments from the LCD of TDP-43 form steric zippers
For structural studies we targeted segments throughout the LCD because there is no 
consensus of which region is the amyloidogenic core. The LCD of TDP-43 is an 
unstructured domain composed of approximately 140 amino acid residues. Researchers have 
demonstrated that this region plays a role in aberrant mislocalization and aggregation of 
TDP-43 to the cytoplasm in mice and neuroblastoma cell lines44,45. It was initially 
suggested that the entire LCD, residues 277–414, served as a prion like domain and was the 
minimum fragment required for aggregation46. However, additional studies suggested 
smaller regions within the LCD are sufficient for aggregation and neurodegeneration. In the 
first study, segment 286–331 was identified and shown to form amyloid fibrils and confer 
neurotoxicity on primary cortical neurons47. A second study identified residues 311–360, 
illustrating through NMR and CD studies that this segment undergoes a helix to β-sheet 
transition that initiates aggregation and cytoplasmic inclusion48,49. A third study suggested 
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that segment 342–366 is the minimum toxic core that transitions from a random coil to a β-
sheet50. In short, these studies illustrated that there are several regions of the LCD that can 
be responsible for amyloid-like aggregation.
Our previous studies demonstrated that adhesive cores of amyloid fibrils are composed of 6–
11-residue segments that stack together as steric-zippers22,51. To identify which segments 
from the LCD of TDP-43 might be responsible for TDP-43 aggregation, we consulted 
ZipperDB52, (URL: https://services.mbi.ucla.edu/zipperdb). We selected the top 10 hits 
scored by their adhesive energies (supplementary table 1). Additionally, we also selected 
segments rich in glutamine and asparagine because the C-terminus of TDP-43 is a prion-like 
sequence and these two residues are important for prion aggregation53,54. Lastly, we selected 
two segments based on a double mutation reported to reduce TDP-43 aggregation48 (see 
methods and materials section for detailed segment selection), In total, we targeted fifteen 
segments in the LCD of TDP-43 (supplementary table 1).
Crystal structures revealed that six of the segments formed steric-zippers: 300GNNQGSN306, 
321AMMAAA326, 328AALQSS333, 333SWGMMGMLASQ343, 370GNNSYS375, and 
396GFNGGFG402 (Fig. 1A and B, Table 1). These structures demonstrated tight side chain 
interdigitation, like the previously reported zippers in other amyloidogenic proteins, such as 
β-amyloid51 and Tau55. All three six structures are composed of in-register sheets22. 
Segments 321AMMAAA326 and 333SWGMMGMLASQ343 form anti-parallel sheets 
(Supplementary Fig. 1) while the other four segments form parallel sheets.
Segments 300GNNQGSN306, 328AALQSS333 and 370GNNSYS375 all form Class 1 steric 
zippers in which the β-sheets are mated face-to-face with the same edges of the sheet 
oriented up the fibril (Fig. 1B)22,51. These Class 1 structures have two distinct interfaces 
(labeled as IF1 and IF2 in Fig.1B). Segments 321AMMAAA326 and 
333SWGMMGMLASQ343 are Class 7 steric zippers with face-to-back and up-up orientation. 
Segment 396GFNGGFG402 forms a Class 4 steric zipper with face-to-back β-sheets and up-
down orientation (Fig. 1B)51. These Class 7 and Class 4 structures have one unique 
interface. The area buried (Ab) and shape complementary (Sc) of all interfaces are labeled in 
Fig. 1B51.
Six zipper segments are important for pathogenic TDP-43 aggregation
To investigate the connection between our steric-zipper structures and the pathogenic 
aggregates of TDP-43, we designed mutations to disrupt the zipper structures and tested 
their influence on aggregation of the TDP-43 protein. The segment we chose to represent 
pathogenic TDP-43 aggregation contains residues D-414 because it is a pathogenic segment 
of TDP-43 that was identified from FTLD brains40. We term this segment TDP-CTF, where 
CTF stands for C-terminal fragment. We disrupted steric-zipper formation by substituting 
tryptophan at the central residue of the sheet-sheet interface; its bulk imposes steric 
hindrance. We designed 8 mutations, Q303W and G304W targeting interface 2 and 1 of 
300GNNQGSN306, respectively; A324W targeting the interface of 321AMMAAA326; 
L330W and Q331W targeting interfaces 1 and 2 of 328AALQSS333, respectively; M337W 
targeting the interface of 333SWGMMGMLASQ343; S373W targeting interface 2 of 
370GNNSYS375; and G399W targeting the interface of 396GFNGGFG402.We did not design 
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a mutation in interface 1 of 370GNNSYS375, since the interaction is relatively weak as 
judged by its small area buried.
Our mutagenesis results indicate that all six short segments are important for TDP-43-CTF 
aggregation. We achieved an aggregate-free starting point by conjugating TDP-CTF wild 
type and its mutants with a SUMO tag (Fig.2a, top panel). Aggregation was initiated by 
ULP1 protease removal of the SUMO tag (Supplementary Fig.2). After 30 min of incubation 
on ice approximately half of the SUMO-free TDP-CTF aggregated, as judged by the pellet 
fraction after centrifugation (Fig.2a, middle panel). In contrast, most of the SUMO-free 
mutants remained soluble, except G304W. After overnight incubation, cleavage of the 
SUMO-tag was nearly complete and all SUMO-free TDP-CTF wild type was in the pellet 
(Fig.2a, bottom panel). However, aggregation was incomplete for several mutants, 
displaying soluble TDP-CTF mutant material in the supernatant, including Q330W, A324W, 
M337W, L330W, Q331W and G399W. These results indicate that interface 2 of 
300GNNQGSN306, the interface of 321AMMAAA326, interfaces 1 and 2 of 328AALQSS333, 
the interface of 333SWGMMGMLASQ343, interface 2 of 370GNNSYS375, and the interface 
of 396GFNGGFG402 are important for pathogenic aggregation of TDP-43. Potentially, these 
segments could facilitate pathogenic aggregation of wild type TDP-43 by forming the same 
steric-zipper structures we report here. Three of these zippers are located within the region 
318–343, previously identified as the amyloidogenic core essential for TDP-43 
aggregation48. This correlation is significant given that it covers a relatively small region 
compared to the whole LCD (26 residues out of 140). Moreover, a previous discovery that 
the double mutation A324E-M337E reduces TDP-43 aggregation48 is consistent with our 
expectation that these substitutions create steric hindrance and electrostatic repulsion, 
thereby disrupting steric-zipper interfaces of 321AMMAAA326 and 
333SWGMMGMLASQ343. These results suggest that these segments are important for 
pathogenic aggregation of TDP-43, and the steric-zipper structures we report here may 
represent the structure of the aggregation core.
To further validate the role of these segments in TDP-43 aggregation, we compared the fibril 
diffraction of the low complexity domain of TDP-43 with the simulated diffraction of the 
zipper structures. We carried out fibril diffraction on TDP-LCD that contains residues 274–
414 and was expressed using the same SUMO-tag strategy employed previously 
(Supplementary Fig.2). TDP-LCD formed long extended amyloid-like fibrils around 15 nm 
in diameter (Fig.2B), similar to the fibrils formed by TDP-43 in ALS patients41. The fibril 
diffraction pattern shows the rings at 10 Å and 4.8 Å, the signature feature of amyloid 
fibrils22. In comparison, electron micrographs of the six zipper-forming segments reveal 
microcrystals (Fig. 2B). We have shown these crystals are composed of cross-β assemblies. 
That is, the architecture revealed by the crystal structures of the segments is consistent with 
the cross-β signature of the TDP-LCD. Simulated fibril diffraction patterns calculated from 
their crystal structures are comparable with experimental diffraction of the TDP-LCD fibril 
(Fig. 2B); the differences correspond to variation in sheet-to-sheet distance among segments.
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Segment 312–317 of the LCD forms a kinked structure that is disrupted by the A315T and 
A315E familial ALS mutants
In addition to pathogenic aggregation, TDP-43 is also involved in functional aggregation, 
such as SG formation. In SG assembly, the LCDs of SG-proteins are reported to be the key 
regions responsible for this reversible aggregation1–3. To further explore the role of the LCD 
in the functional aggregation of TDP-43, we focused on segments that have the potential to 
contribute to SG formation. The McKnight laboratory previously discovered that glycine 
residues flanked by aromatic side chains are features of hydrogel formation of the LCD of 
the protein FUS2. The hydrogel they studied is a reversible aggregate formed in vitro 
composed of reversible amyloid fibrils that trap a large amount of water, and is potentially 
relevant to SG formation in vivo56. They showed that replacement of aromatic residues in 
the LCD disrupted this hydrogel formation2, which led to the hypothesis that aromatic 
residues play a role in SG assembly. For this reason, our recent study focused on the 
segments of the LCD of SG proteins that contain an aromatic residue and two proximal 
small or polar residues21. Structural studies of these segments in FUS and hnRNPA1 
revealed pairs of kinked sheets, defined as LARKS (Low complexity, Aromatic-Rich, 
Kinked Segments), that display weak van der Waals interactions between mating sheets. 
Further research suggests the connection of LARKS with protein adhesion of LCDs in 
reversible aggregation formation21.
In the present study, we find 312NFGAFS317, in the LCD of TDP-43, has similar amino acid 
composition and also forms labile aggregates and LARKS (Fig. 3). This suggests that 
TDP-43 can adopt the same mechanism of SG-formation previously hypothesized for FUS 
and hnRNPA1. Under EM, 312NFGAFS317 forms microcrystals (Fig. 3A). These 
microcrystals are labile, meaning they fully dissolve when treated with ≥1% SDS and heat to 
70°C for 15 minutes. Their lability was observed by diminished turbidity (Fig. 3B). This 
behavior is similar to hydrogels formed by LCDs of SG-proteins, which re-solubilize by 
treatment with SDS and heat2, unlike pathogenic amyloid fibrils such as β-amyloid fibrils 
(Supplementary Fig. 3A). The structure of 312NFGAFS317 reveals a kinked backbone (Fig. 
3C), similar to other LARKS21. The kink occurs at Phe316 and has a Ramachandran angles 
of a left-handed α-helix. The kinked backbone makes two phenylalanine residues at 
positions 2 and 5 face the same side of the sheet, whereas a canonical β-sheet places the odd 
numbered sidechains on one face and the even numbered sidechains on the opposite face51. 
The subsequent packing of mating strands creates two different interfaces. Here we see that 
all the aromatic residues pack near to each other creating a hydrophobic, aromatic interface. 
The other interface is held together by the hydrogen-bonded interactions of the asparagine 
side chains. Both interfaces are weaker than most zipper structures as indicated by the 
relative low surface area buried, and consistent with the observation that these assemblies 
are labile under treatment with SDS and heat.
We observe that 312NFGAFS317 forms a LARKS structure and its microcrystalline 
aggregates are labile, thus providing another example of LARKS with a potential role in SG 
formation, and an opportunity to investigate the influence of pathogenic variants of the 
putative key segment of functional aggregation. Within the NFGAFS segment, there are two 
ALS-linked familial variants: A315T and A315E47,57. Both of these variants have been 
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shown to increase redistribution of TDP-43 to the cytoplasm and increase neuronal death as 
compared to the reference sequence58–61. Additionally, previous studies have shown that 
disease-causing mutations in SG-proteins are associated with accumulation of persistent 
SGs62–64. However the molecular mechanism of transformation of SGs to irreversible 
aggregates has remained elusive. Here we studied the structure and biochemical behavior of 
312NFGTFS31, 312NFGEFS317, and 312NFGpTFS317 where pT stands for phosphorylated 
threonine. We studied 312NFGpTFS317 because TDP-43 is found to be hyperphosphorylated 
in ALS patients35, and the A315T mutation may create a new phosphorylation site in vivo.
All three of these mutant segments formed microcrystals under EM (Fig. 3A). 
312NFGEFS317 and 312NFGpTFS317 aggregates were irreversible under the same SDS and 
heat denaturing assay as 312NFGAFS317. 312NFGTFS317 aggregates, however, were still 
labile (Fig. 3B). These results indicated that the stabilities of the mutant segments A315E 
and A315pT were significantly enhanced as compared to that of 312NFGAFS317.
To better understand the biochemical findings, we determined the structures of all three 
mutant segments. All three structures are composed of kinked, in-register, parallel sheets; 
however the kink positions differ. In 312NFGAFS317 the kink occurs at Phe316. In the case 
of 312NFGTFS317 and 312NFGEFS317, the kink occurs at Gly314; and the 312NFGpTFS317 
structure is kinked at two residues, Phe313 and Gly314. Despite the different positions of the 
kinks, all of the kinks result in the two phenylalanine residues facing the same side of the 
sheet (Fig. 3C).
Further analysis of the structures illustrates that the packing of sheets in both 312NFGTFS317 
and 312NFGpTFS317 are face-to-face, as in 312NFGAFS31. Both have two distinct interfaces 
of mating strands, one dry interface formed by hydrophobic residues (mainly phenylalanine 
residues, labeled as IF1 in Fig. 3C) and one wet interface formed by mostly hydrophilic 
residues (labeled as IF2 in Fig. 3C). The packing of 312NFGEFS317 is face-to-back so its 
two interfaces are identical, with hydrophobic interactions in the middle and hydrophilic 
interactions on both sides. For the 312NFGpTFS317 structure, the phosphate is clearly 
observed in the Fo-Fc omit map (Supplementary Fig. 3B). To our knowledge, this is the first 
time a post-translational modification has been reported for an amyloid mimetic structure. 
The enhanced stability of the A315E and A315pT of 312NFGAFS317 assemblies can be 
explained by the increased interface strengths, indicated by area buried for the dry interface 
and hydrogen network of the wet interface. The area buried for the dry interface increased 
significantly from 63.0 Å2/chain in 312NFGAFS317 to 137.0 Å2/chain in 312NFGEFS317 and 
175.6 Å2/chain in 312NFGpTFS317 (Fig. 3C). In the case of 312NFGpTFS317, increased 
buried area results from the four phenylalanine residues of two strands perfectly 
interdigitating with each other. Additionally, on the wet interface, the side chains of Glu315 
and pThr315 create a hydrogen bonding network, which further strengthens the assembly 
(Supplementary Fig. 3C). This stacking of negatively charged Glu315 and pThr315 is 
facilitated by the acidic pH of crystallization conditions, in which the residual TFA from 
peptide synthesis significantly decreases the pH, and results in partially protonated 
glutamate and P-threonine side chains (see discussion). For 312NFGTFS317, the area buried 
for dry interface and hydrogen network for the wet interface is similar that of 
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312NFGAFS317, which is consistent with the observation that 312NFGTFS317 has similar 
behavior in our denaturing assay as 312NFGAFS317.
In summary, we find that the 312NFGAFS317 segment of TDP-43 forms a kinked β-sheet 
structure—a LARKS—which is labile. We find that two familial variants within this 
segment, A315T and A315E, together with phosphorylation, strengthen the reference 
sequence assembly and making it irreversible by creating a more stable structure with 
stronger interaction between each the sheets. These results further support our hypothesis 
that LARKS are the potential molecular mechanism of functional, reversible aggregate 
formation, by showing that LARKS exist in another SG-forming protein, TDP-43. 
Moreover, these results indicate that the pathogenic mutations and or post-translational 
modifications can strengthen LARKS and drive SG-proteins towards pathogenic 
aggregation.
Discussion
Our previous studies suggested connections of cross-β structures to both amyloid 
aggregation through steric-zippers forming irreversible pathogenic fibrils22 and LARKS 
forming reversible hydrogels and possibly membrane-less organelles21. In this study, we 
determined structures of segments from the LCD of TDP-43 and found that that this domain 
has the capacity to form both steric-zippers and LARKS. This is consistent with the dual 
nature of the TDP-43 LCD which can drive aggregation of the protein into either functional 
SG aggregates or into pathogenic amyloid fibrils as in ALS or FTLD. In Figure 4 we present 
a speculative model that incorporates our findings and explains how SG assembly might lead 
to pathogenic assembly. In physiological conditions, TDP-43 can execute its normal 
functions without irreversible aggregation, even though steric-zipper (red bars) and LARKS 
(kinked blue bars) segments exist in their sequences (Fig. 4, top panel). In pathogenic 
conditions, the steric-zipper forming segments interact with each other to form irreversible 
assemblies, driving the protein into pathogenic amyloid fibrils (Fig. 4, left pathway). In 
stress conditions, the LARKS forming segments interact with each other to form reversible 
assemblies and drive the protein to functional aggregates such as SGs. Since functional 
assemblies are reversible1,2,14, the aggregation of proteins can be reversed when stress is 
relieved (Fig. 4, right pathway). Numerous factors are believed to influence the fate of the 
proteins, including intra/inter-cellular signals, chaperones, RNA binding, protein folding, 
microenvironments such as pH, protein concentration, etc. Here, our study suggests that the 
mutations and or post-translational modifications can also change the pathway of assembly 
by directly changing the character of assembly-driving segments (Fig. 4, middle pathway). 
As exemplified by A315E and A315pT, the mutation and phosphorylation strengthen the 
312NFGAFS317 assembly, converting a labile LARKS to irreversible aggregates. Our 
hypothesis is that under conditions that favor SGs, LARKS segments interact with each 
other, and should one or more of them convert to an irreversible structure, the protein may 
form a pathological, irreversible assembly.
The mechanism represented in Figure 4 may apply for other regions of TDP-43 and other 
SG-forming proteins. The 312NFGAFS317 segment is not the only region proposed to be 
important for reversible aggregation of TDP-43; residues 320–340 have been reported to be 
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involved in granule formation3,65. Applying a threading algorithm for predicting LARKS 
from amino acid sequence, we predicted additional LARKS in the LCD of TDP-4321. We 
compared the LARKS predictions with the familial variants reported on TDP-43 LCD, and 
found that 28 out of 42 reported familial variants are in the regions of predicted LARKS 
(supplementary table 2). This observation supports our hypothesis that the mechanism of 
conversion of A315E and A315pT on 312NFGAFS317 may be a general mechanism.
Notice that both 312NFGEFS317 and 312NFGpTFS317 crystals were grown at acidic pH, 
which facilitated the stacking of glutamate and phosphorylated threonine residues. A recent 
study also shows that decrease in pH drives phase separation in yeast and in in vitro 
systems66. This observation suggests the importance of pH on SG formation and the role of 
pH in transition of SG to pathogenic aggregation.
In this study, we also reported six steric-zipper structures from LCD of TDP-43, and showed 
the connection between these structures with pathogenic aggregates of TDP-43 by 
mutagenesis experiments. The observation that all six segments are important for TDP-43 
aggregation, suggests a segmental polymorphism, meaning the aggregation of TDP-43 can 
be formed via multiple cores. Although recent structural studies have shown that the 
amyloid fibril core usually contains tens of residues (e.g. cryo-EM structures of Tau67), our 
study on short peptides facilitates the research of amyloidogenic proteins by identifying the 
high-resolution structures of core aggregation-prone segments, and more importantly, by 
providing structural insights for inhibitor designs. By designing peptide inhibitors that bind 
to the ends of steric-zipper structures and cap their growth, we have successfully developed 
the inhibitors for aggregation of several amyloidogenic proteins, including p5368 and Tau55. 
The zipper structures we reported here will provide the opportunity for structure-based 
design of TDP-43 inhibitors.
In summary, the present study provides atomic-resolution structures of irreversible and 
reversible aggregates of segments of TDP-43, and the possible roles of familial mutations 
and or post-translational modifications in the interconversion of these two distinct 
aggregation pathways.
Online Methods
Selection and Generation of TDP-43 Peptide Targets
We chose our peptides of interest by a combination of computational prediction and 
literature reports (supplementary table 1). For computational prediction, we selected the 
segments that contain high rank predictions from ZipperDB (ranked by the predicted Rosetta 
energy). From literature reports, we have selected the segments containing the features 
important for LCD aggregation. First, the LCD of TDP-43 is believed to be a prion-like 
domain, and glutamine and asparagine residues are found to be important for prion 
aggregation53,54, so we selected three segments from LCD of TDP-43 that have the highest 
Gln and Asn density. These three segments are GNNQGSN (4 out of 7), ASQQNQ (4 out of 
6) and GNNQNQ (5 out of 6); the latter two were also identified by ZipperDB. Second, 
aromatic residues are reported to be important in LCD aggregation2, so we selected two 
segments from the LCD of TDP-43 that have multiple aromatic residues close to each other; 
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these are NFGAFS (two residues between two phenylalanine residues) and GFNGGFG 
(three residues between two phenylalanine residues). Third, the A324E-M337E double 
mutation is reported to reduce TDP-43 aggregation48, so AMMAAA and 
SWGMMGMLASQ were selected to study the molecular mechanism of this double 
mutation. All peptides were purchased from Genscript at a purity of 95% or higher. Notice 
that from fifteen peptides we selected, we determined the structures for ten of them. The 
other segments we selected (supplementary table 1), failed to generate structures because of 
poor crystal formation or poor quality of crystal diffraction.
Peptide Aggregates Formation
All peptide segments were dissolved in phosphate buffered saline (PBS) at pH 7.5 to a final 
concentration of 20mM. Samples were then incubated at 37°C in a Torrey Pine Scientific 
shaker at level 9 for 80 hours. Samples were examined by TEM following fibril formation.
Construct design
TDP-CTF (208–414) was designed to mimic the pathological fragment of TDP-43 found in 
FTLD brain, and the low complexity domain of TDP-43 (TDP-LCD, 274–414) was also 
designed. Both TDP-43 fragments was conjugated to the carboxyl-terminus of small 
ubiquitin-like modifier (SUMO) proteins to increase its solubility and prevent its 
aggregation during expression and purification. The SUMO protein was also conjugated 
with (His)6-tag on its amino-terminus for easier purification. The SUMO-TDP constructs 
were inserted into a pET28a vector with following expressed sequences:
SUMO-TDP-CTF: 
MGSSHHHHHHGSGLVPRGSASMSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIF
FKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHR
EQIGGREFFSQYGDVMDVFIPKPFRAFAFVTFADDQIAQSLCGEDLIIKGISVHISNAEP
KHNSNRQLERSGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAF
SINPAMMAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGS
GNNSYSGSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM
SUMO-TDP-LCD: 
MGSSHHHHHHGSGLVPRGSASMSDSEVNQEAKPEVKPEVKPETHINLKVSDGSSEIF
FKIKKTTPLRRLMEAFAKRQGKEMDSLRFLYDGIRIQADQTPEDLDMEDNDIIEAHR
EQIGGGRFGGNPGGFGNQGGFGNSRGGGAGLGNNQGSNMGGGMNFGAFSINPAM
MAAAQAALQSSWGMMGMLASQQNQSGPSGNNQNQGNMQREPNQAFGSGNNSYS
GSNSGAAIGWGSASNAGSGSGFNGGFGSSMDSKSSGWGM
Protein purification and validation
Both SUMO-TDP-CTF and SUMO-TDP-LCD protein was expressed in Escherichia coli 
BL21 (DE3) strain. Bacterial cells were cultured in LB media supplemented with 50 µg/ml 
kanamycin at 37 °C to an OD600 of 0.6–0.8. Protein expression was induced with 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG) at 25 °C for 3 hours. Cells were harvested 
and re-suspended in 20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 20 mM Imidazole, 10% (v/v) 
glycerol, supplemented with 1% (v/v) Halt Protease Inhibitor single-use cocktail (Thermo 
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Scientific). The re-suspension solution was sonicated (3s on/3s off cycle, 10 mins) and the 
supernatant solution was collected after centrifugation (24,000 × g for 20 mins). The 
supernatant solution was mixed with homemade NucA nuclease (5000 U per liter of cell 
culture) and filtered before load to HisTrap HP column (GE health care). The HisTrap 
column was equalized with 20 mM Tris-HCl, pH 8.0, 500 mM NaCl, 20 mM Imidazole 
before loading of supernatant solution, and washed with 20 mM Tris-HCl, pH 8.0, 500 mM 
NaCl, 200 mM Imidazole after loading. The protein expected was eluted by 20 mM Tris-
HCl, pH 8.0, 500 mM NaCl, 500 mM Imidazole and concentrated by Amicon Ultra-15 
centrifugal filters (Millipore) to at least 2 mg/ml (10 fold higher than the working 
concentration of aggregation assays). SUMO-TDP-LCD was concentrated to 10 mg/ml (10 
fold higher than its fibril formation concentration).
To validate the cleavage of SUMO-tag and existence of TDP fragment, purified SUMO-
TDP-CTF and SUMO-TDP-LCD was diluted into 0.2 mg/ml with 20 mM Tris-HCl, pH 8.0, 
150 mM NaCl, 10 µM DTT, mixed with 100:1 (weight basis) homemade ULP1 protease, 
and incubated on ice. Samples were taken before and 1 hour after adding ULP1 protease, 
and separated by NuPAGE 4–12% Bir-Tris gel (Invitrogen). The pellet of SUMO-TDP-LCD 
was also collected and sampled from fibril formation assay and loaded to the same gel. The 
SDS-PAGE was stained by coomassie blue, or probed with TDP-43 polyclonal antibody 
(Invitrogen, catalog number PA5-27221, 1:1000 dilution) and Anti-Rabbit IgG (whole 
molecule)-Peroxidase antibody (Sigma, catalog number A0545, 1:5000 dilution) after 
transferred to a nitrocellulose membrane (Invitrogen). The membrane was visualized with 
SuperSignal West Pico Chemiluminescent Substrate kit (Thermo Scientific) and BIOMAX 
Light Film (Carestream).
Fibril formation and diffraction of TDP-LCD
SUMO-TDP-LCD was diluted into 1 mg/ml with the same dilution buffer used in 
aggregation assays of TDP-CTF, and mixed with 100:1 (weight basis) homemade ULP1 
protease. The fibril was formed by shaking the solution at 37 °C for 3 days and sitting it on 
bench for another 2 days. The fibril was collected by centrifugation at 9,000 × g for 5 mins 
and washed by water for 2 times. The fibril was sampled for TEM analysis and SDS-PAGE, 
and then concentrated to 2% of the original volume by centrifugation and removal of 
supernatant. The concentrated solution was loaded between two siliconized glass capillaries 
with their heads facing each other. The solution was then dried out and the fibril remained 
on one of the capillary heads in solid form. The capillary with fibril was mounted on an in-
house X-ray machine and the fibril was shot by X-ray for 3 mins. The diffraction pattern was 
detected and recorded by a CCD detector.
Fibril diffraction simulation of zipper forming segments
The crystal structures of zipper forming segments were used for generation of fibril 
diffraction simulation. To simulate the fibril diffraction patterns, the space group of each 
crystal structure was expanded into P1, and structure factors were calculated using the CCP4 
program sfall69. The diffraction patterns were cylindrically averaged 180 degrees around the 
fibril axis using custom written software.
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Negative Stain Transmission Electron Microscopy (TEM)
Samples for TEM were prepared by applying 5 µL of sample on hydrophilic 400 mesh 
carbon-coated formvar support films mounted on copper grids (Ted Pella, Inc.). The fibrils 
were allowed to adhere for 4 min and washed twice with water. The samples were then 
stained for 2 min with 2% uranyl acetate, leaving a few nanoliters of stain on the grid. Grids 
were allowed to dry for 1 minute before storage. Each grid was inspected on a T12 (FEI) 
microscope.
Aggregation assays of TDP-CTF
SUMO-TDP-CTF wild type and its mutants were diluted into 0.2 mg/ml with 20 mM Tris-
HCl, pH 8.0, 150 mM NaCl, 10 µM DTT and filtered by 0.1 µm Ultrafree-MC-VV 
centrifugal filters (Millipore). The filtered solution was mixed with 100:1 (weight basis) 
homemade ULP1 protease and incubated on ice to remove the SUMO-tag from TDP-CTF. 
The samples were taken before and 30 mins after adding the protease, and the 30-minute-
samples were divided into supernatant and pellet fraction by centrifugation at 18,000 × g for 
3 mins at 4 °C. The pellet fraction was re-suspended with the same buffer used in dilution 
and with the same volume of the original samples. The samples were mixed with 3:1 (v/v) of 
NuPAGE LDS sample buffer (Invitrogen) and heated to 100 °C for 10 mins. After the 30-
minute-samples were taken, the cleavage solutions were moved to refrigerator (4 °C) and 
incubated overnight. The overnight samples were then taken and prepared same as 30-
minute-samples. All samples were loaded to and separated by NuPAGE 4–12% Bis-Tris gels 
(Invitrogen) and stained by coomassie blue. To make better comparisons, the samples of 
wild type TDP-CTF were loaded to both gels when the samples taken from the same time 
point were split into two gels because of loading well limitation.
Denaturing assays of 312NFGAFS317 and its variants
Twenty-percent (m/v) SDS solution (in water) was diluted to 15%, 10% and 5% (m/v) by 
water, and 20% (v/v) of SDS-water stocks or water were mixed with 80% (v/v) of PBS to 
make SDS-PBS stocks with 4%, 3%, 2%, 1% and 0% (m/v) of SDS. SDS-PBS stocks with 
varies SDS content were mixed with 20 mM peptide-PBS solution in 1:1 volume ratio to get 
final peptide solutions with 2%, 1.5%, 1%, 0.5% and 0% (m/v) SDS. All solutions were 
divided into 3 PCR tubes (5 µl per tube), and the solutions contain 2%, 1.5%, 1% and 0.5% 
(m/v) SDS were heated to 70 °C for 15 mins by a thermocycler. The OD340 of solutions in 
each tube were measured by P330 NanoPhotometer (Implen), and the readings from same 
peptide were normalized to the mean values of the solutions contain no SDS and without 
heating.
Aβ fibril denaturing assay
Aβ purification and preparation please see our previous study70. Aβ1–42 was diluted into 50 
µM with PBS buffer, and incubated at 37 °C overnight to form Aβ fibrils. The fibril solution 
was mixed with 10% (v/v) of 20% (m/v) SDS stock to make 2% (m/v) final SDS 
concentration, and heated to 70 °C for 15 mins. The samples were taken before and after 
adding SDS and heating, and analyzed by TEM.
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Crystallization
All crystals, except 312NFGEFS317, 312NFGpTFS317 and 333SWGMMGMLASQ343 were 
grown by hanging drop vapor diffusion. 300GNNQGSN306 was dissolved in water to a final 
concentration of 10 mg/ml. The reservoir solution was optimized around the initial hit of 
0.2M sodium sulfate, 0.1M Bis tris propane pH 7.5, and 20% (w/v) PEG 3350. Hanging 
drops contained a 2:1 solution of protein: reservoir.
321AMMAAA326 was dissolved in water to a final concentration of 10mg/ml, supplemented 
with 29.4 mM of LiOH. Crystals were grown over a reservoir solution containing 1.3 M 
Ammonium Phosphate and 0.1 M sodium acetate pH 6.27. Hanging drops contained a 1:2 
solution of protein: reservoir.
328AALQSS333 was dissolved in water to a final concentration of 10mg/ml. Crystals were 
grown over a reservoir solution containing 0.01 M nickel chloride, 0.1 M Tris pH 8.5 and 
20% (w/v) PDG 2000. Hanging drops contained a 2:1 solution of protein: reservoir.
370GNNSYS375 was dissolved in water to a final concentration of 10mg/mL. Crystals were 
grown over a reservoir solution containing 0.2M sodium nitrate, 0.1M Bis tris propane pH 
8.5, and 20% (w/v) PEG 3350. Hanging drops contained a 2:1 solution of protein: reservoir.
396GFNGGFG402 was dissolved in water to a final concentration of 12 mg/mL. Crystals 
formed with the reservoir solution: 800 mM Sodium phosphate monobasic/ 1200 mM 
Potassium phosphate dibasic, 100 mM Sodium acetate/ Acetic acid pH 4.5. Hanging drops 
contained a 2:1 solution of protein: reservoir.
312NFGAFS317 was dissolved in water to a final concentration of 11mg/mL. Crystals 
formed with a reservoir solution of 0.1M phosphate/citrate pH 4.2, 40% w/v ethanol and 5% 
w/v PEG 1,000. The drops contained a 2:1 ratio of protein solution: reservoir.
312NFGTFS317 was dissolved in water to a final concentration of 11mg/mL. Crystals formed 
with a reservoir solution of 0.2M ammonium acetate, 0.1M sodium acetate pH 4.6, and 30% 
w/v PEG 4,000. The drops contained a 2:1 ratio of protein solution: reservoir.
312NFGEFS317, 312NFGpTFS317 and 333SWGMMGMLASQ343 were dissolved in PBS (pH 
7.5) to a final concentration of 20mM. The peptide solution was shaken at 37°C in a Torrey 
Pines shaker at level 9 for 80 hours. To better understand the stacking of glutamate and 
phosphorylated threonine in 312NFGEFS317 and 312NFGpTFS317 structures, the pH of both 
peptide solutions was tested by MColorpHast pH-indicator strips (Millipore) and the pH of 
both solutions was around 4. For 312NFGpTFS317, initial crystals growing from shaking 
diffracted poorly, and in order to get better diffracting crystals, an additional round of crystal 
seeding was performed. Fresh made 20 mM 312NFGpTFS317 PBS solution was filtered and 
mixed with 2% (v/v) of pre-formed 312NFGpTFS317 crystals, and incubate at 37°C without 
shaking for 120 hours. Diffraction data was collected from seeded crystals, and the initial 
crystals were used in denaturing assay and EM observation showing in Fig.3.
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X-ray Diffraction Data Collection and Processing
All x-ray diffraction data were collected at beamline 24-ID-E of the Advanced Photon 
Source, Argonne National Laboratory, Argonne, IL, USA, at a wavelength of 0.971 Å and 
temperature of 100 K. For NFGAFS, data were collected at 5° oscillations and 130 mm 
detector distance. Detector ADSC Q315 was used. Indexing and integration were done using 
XDS in P212121 and scaled with XSCALE to 1.1 Å resolution71. The data were imported 
using the CCP4 suite69. Molecular replacement was done using Phaser72. Initial models of 
different idealized polyalanine β-strands did not yield a structure. The final model used was 
a kinked strand with the sequence NFGAAS, which was based on the truncated structure of 
NNFGAIL73. The model was manually adjusted over 3 cycles to the correct sequence and 
rotamer orientation in COOT74. The atomic model was refined by Phenix75 with a final 
Rwork/Rfree of 13.3/16.0% and 100% of Ramachandran angles favored.
For NFGTFS, data were collected at 5° oscillations and 125 mm detector distance. Detector 
ADSC Q315 was used. Indexing and integration was done using XDS in P21 and scaled with 
XSCALE to 1.0Å resolution71. The data were imported using the CCP4 suite69. The 
structure was solved by direct methods using the program SHELX76. The model was 
manually adjusted over 3 cycles to the correct sequence and rotamer orientation in COOT74. 
The atomic model was refined by Refmac77 with a final Rwork/Rfree of 8.7/9.3% and 100% 
of Ramachandran angles favored.
For GFNGGFG, data were collected at 5° oscillations and 150 mm detector distance. 
Detector ADSC Q315 was used. Indexing and integration was done using Denzo in P1 and 
scaled with SCALEPACK to 1.25Å resolution78. The data were imported using the CCP4 
suite69. Molecular replacement was done using Phaser72. Initial models of different idealized 
polyalanine β-strands did not yield a structure. The final model used was two kinked strands 
with the sequence GFAGG, which was based on the truncated structure of SYSGYS21. The 
model was manually refined using Phenix75 over 4 cycles to the correct 7 residue sequence 
and rotamer orientation in COOT74. The atomic model has a final Rwork/Rfree of 15.2/16.8% 
and 100% of Ramachandran angles favored.
For AMMAAA, data were collected at 5° oscillations and 130 mm detector distance. 
Detector EIGER 16M was used. Indexing and integration was done using XDS in P212121 
and scaled with XSCALE to 1.2Å resolution71. The data were imported using the CCP4 
suite69. Molecular replacement was done using Phaser72 with an idealized polyalanine β-
strand (AAAAAA). The model was manually adjusted over 14 cycles to the correct 6 
residue sequence and rotamer orientation in COOT74. The atomic model was refined by 
Refmac77 with a final Rwork/Rfree of 19.8/21.8% and 100% of Ramachandran angles 
favored.
For AALQSS, data were collected at 5° oscillations and 130 mm detector distance. Detector 
EIGER 16M was used. Indexing and integration was done using XDS in P212121 and scaled 
with XSCALE to 1.1 Å resolution71. The data were imported using the CCP4 suite69. The 
structure was solved by direct methods using the program SHELX76. The model was 
manually adjusted over 13 cycles to the correct 6 residue sequence and rotamer orientation 
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in COOT74. The atomic model was refined by Refmac77 with a final Rwork/Rfree of 
19.5/24.3% and 100% of Ramachandran angles favored.
For GNNQGSN, data were collected at 5° oscillations and 125 mm detector distance. 
Detector ADSC Q315 was used. Indexing and integration was done using XDS71 in C2 and 
scaled with SCALEPACK79 to 1.8Å resolution. The data were imported using the CCP4 
suite69. Molecular replacement was done using Phaser72 with an idealized β-strand of the 
sequence GNNAGA. The model was manually adjusted over 38 cycles to the correct 7 
residue sequence and rotamer orientation in COOT74. The atomic model was refined by 
Refmac77 with a final Rwork/Rfree of 18.3/19.4% and 80% of Ramachandran angles favored 
as well as 20% allowed.
For GNNSYS, data were collected at 3° oscillations and 125mm detector distance. Detector 
ADSC Q315 was used. Indexing and integration was done using Denzo in P212121 and 
scaled with SCALEPACK to 1.00Å resolution78. The data were imported using the CCP4 
suite69. Molecular replacement was done using Phaser with an idealized 5 residue 
polyalanine β-strand72. The model was manually refined using Phenix over 2 cycles to the 
correct 6 residue sequence and rotamer orientation in COOT74,75. The atomic model has a 
final Rwork/Rfree of 15.5/18.1% and 100% of Ramachandran angles favored.
MicroED Data Collection and Processing
The MicroED data were collected using the same protocol as Rodriguez et al. with minor 
differences detailed below80–82. Data was collected at HHMI Janelia Research Campus 
using the Tecnai F20 TEM operating at 200 kV recorded using a bottom mount TVIPS F416 
CMOS camera.
For NFGEFS, Individual image frames were exposed for 3s per image. During each 
exposure, crystals were continuously rotated within the beam at a rate of 0.2° per second. 
Diffraction data were collected and merged from 4 individual crystals. Indexing and 
integration were done using XDS71 in P21212 and scaled with SCALEPACK79 to 1.0Å 
resolution. The data was imported using the CCP4 suite69. The structure was solved by 
direct methods using the program SHELX76. The model was manually adjusted over 4 
cycles to the correct sequence and rotamer orientation in COOT74. The atomic model was 
refined by Refmac77 with a final Rwork/Rfree of 22.0/27.0% and 75% of Ramachandran 
angles favored as well as 25% allowed.
For NFGpTFS, Individual image frames were exposed for 3s per image. During each 
exposure, crystals were continuously rotated within the beam at a rate of 0.295° per second. 
Diffraction data was collected on a single crystal. Indexing and integration were done using 
XDS in P212121 and scaled with XSCALE to 0.75 Å resolution71. The data was imported 
using the CCP4 suite69. The structure was solved by direct methods using the program 
SHELX76. The model was manually adjusted over 16 cycles to the correct sequence and 
rotamer orientation in COOT74. The atomic model was refined by Refmac77 with a final 
Rwork/Rfree of 23.2/25.1% and 100% of Ramachandran angles favored.
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For SWGMMGMLASQ, individual images were exposed for 2s. During each exposure, the 
crystals were continuously rotated within the beam at a rate of 0.315° per second. 
Diffraction data were collected on seven crystals. Indexing and integration were performed 
XDS in space group P1 and scaled with XSCALE to 1.5 Å resolution71. The data were 
imported using the CCP4 suite69. The structure was solved by molecular replacement using 
the program phaser72and a search model consisting of an 9-alanine-long ideal beta-strand. 
The model was manually adjusted in COOT74. The atomic model was refined by Refmac77 
and Buster83 with a final Rwork/Rfree of 28.0/31.3% and 94.5% of Ramachandran angles 
favored as well as 5.5% allowed. These R-factors are higher than expected for a data set of 
this quality. We think the discrepancy is due to a disorder in the crystal. The P1 unit cell 
dimensions of SWGMMGLASQ allow pseudo-merohedral twinning (pseudo space group 
C2). Also, the native Patterson map suggests that the crystal contains a translocation disorder 
(peak at 0.379, −0.264, −0.471 with height of 36% of the origin peak). Attempts to correct 
for these disorders did not improve the R-factors significantly.
Structure Analysis
All images of crystallographic structures were generated in Pymol. Area buried and shape 
complementarity values were calculated based on published methods84,85.
Data Availability
The density maps and atomic coordinates of all models reported here have been deposited to 
the Protein Data Bank (PDB). The MicroED model has also been reported to the EM Data 
Bank. Accession codes are provided here: GNNQGSN (5WKD); AMMAAA (6CEW); 
AALQSS (6CB9); SWGMMGMLASQ (6CFH, EMD-7467); GFNGGFG (5WIQ); 
GNNSYS (5WIA); NFGAFS (5WHN); NFGTFS (5WHP); NFGEFS (5WKB, EMD-8857); 
NFGpTFS (6CF4, EMD-7466). All other data are available upon reasonable requests to the 
authors.
Accession Codes Availability
The fibril diffraction simulation code is available upon request.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Ab Area buried
FUS Fused in sarcoma
LARKS Low complexity aromatic-rich kinked segment
LCD Low complexity domain
CTF C-terminal fragment
LLPS Liquid-liquid phase separation
MicroED Micro electron diffraction
pT phosphorylated threonine
SG stress granule
TDP-43 TAR DNA Binding Protein 43
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Figure 1. Segments from the Low Complexity Domain (LCD) of TDP-43 form steric zippers
(A) Schematic representation of full length TDP-43, the low complexity domain is enlarged 
and the sequences and relative positions of segments for which we determined structures are 
shown. (B) Six steric-zipper structures we determined in this study. For each structure, three 
β-sheets and two interfaces between these sheets are shown, and each sheet shows 5 of its 
thousands of strands. For 300GNNQGSN306, 328AALQSS333 and 370GNNSYS375, two 
interfaces (IF) are distinct and are labeled as IF1 and IF2; For 321AMMAAA326, 
333SWGMMGMLASQ343 and 396GFNGGFG402, all interfaces are identical because of the 
symmetry of packing. The area buried (Ab) and shape complementary (Sc) values for each 
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interface are shown below the structure. Water molecules found in the structure are shown as 
cyan droplets. All the structures are shown in top view, viewed down the fibril axis.
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Figure 2. Validation of steric-zipper forming segments
(A) Aggregation assays of the pathological fragment TDP-CTF (208–414), both wild type 
(wt) and with mutations to block steric-zipper formation. TDP-CTF was conjugated with a 
SUMO protein tag to prevent aggregation, and ULP1 protease was added to remove the 
SUMO tag. TDP-CTF was incubated on ice for 30 mins after cleavage and continued to 
incubate at 4 °C overnight. Samples were taken after incubation and separated into 
supernatant (s) and pellet (p) by centrifugation, and analyzed by SDS-PAGE. Notice that 
TDP-CTF G304W has similar behavior to wild type TDP-CTF, whereas other mutants show 
reduced aggregation compared to wild type. (B) Negative stain EM and fibril diffraction 
pattern of TDP-LCD and steric-zipper segments. TDP-LCD was conjugated with SUMO tag 
and mixed with ULP1 protease to remove SUMO tag. The diffraction pattern of TDP-LCD 
fibrils was acquired by X-ray diffraction and the diffraction patterns of zipper forming 
segments were computationally simulated from their crystal structures. The diffraction 
pattern of TDP-LCD fibrils was overlaid with the ones of zipper-forming segments for 
comparison. Notice that TDP-LCD fibrils generate diffraction rings at 4.8 Å and 10 Å, 
indicating that they have cross-β spines. Scale bar = 200 nm.
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Figure 3. The 312NFGAFS317 segments forms a kinked β-sheet that is strengthened by familial 
variants A315T and A315E
(A) Negative stain EM images of aggregates of 312NFGAFS317 and its variants after 4 days 
of shaking at 37 °C. Scale bar = 200 nm. (B) Denaturing assays of aggregates of 
312NFGAFS317 and its variants. The aggregates of each segment were treated with the 
indicated percentage of SDS, and heat to 70 °C for 15 mins. The absorbance at wavelength 
340 (OD340) of the solution after treatment was measured to represent turbidity. The 
readings from same segment were shown as percentage of the mean values of the segment 
treated with 0% SDS and without heat, and were shown as mean ± SD (n=3 independent 
experiments) with individual data overlaid. (C) Structures of 312NFGAFS317 and its variants. 
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For each structure, six sheets are shown and two interfaces (IF1 and IF2) are labeled 
between three parallel packed sheets. For 312NFGEFS317, the two interfaces between the 
parallel packed sheets are identical because of its face-to-back packing, so the interfaces are 
not labeled. The area buried (Ab) and shape complementary (Sc) values for each interface 
are shown below the structure. Water molecules found in the structure are shown in cyan 
droplets. All the structures are shown viewed down the fibril axis. Notice that the larger 
interfaces in both 312NFGEFS317 and 312NFGpTFS317 are increased over those in 
312NFGAFS317 and 312NFGTFS317, explaining in part their greater stability. See 
Supplementary Fig. 3 for additional hydrogen bond stabilization.
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Figure 4. Speculative model showing the alternative pathways of formation of stress granules 
with pathogenic amyloid
TDP-43 forms several irreversible steric zippers (represented by red bars) and several 
reversible LARKS (represented by blue kinked bars). When performing its normal functions, 
the protein is not aggregated (top panel). Under pathogenic conditions (left pathway), the 
steric zipper segments interact with each other, acting as molecular glue to drive the protein 
into irreversible aggregation, and forming amyloid fibrils; under stress conditions (right 
pathway), the LARKS interact with each other, and acting as molecular Velcro, providing 
adhesion to form a hydrogel as in stress granules; these interactions are reversible. The 
crystal structures of 312NFGAFS317, 312NFGEFS317 and 312NFGpTFS317 show that A315E 
and A315T with phosphorylated Thr can strengthen the LARKS to irreversible aggregates. 
Either mutation or post-translational modifications can act as the agent of conversion 
(middle pathway). Since the involvement of 312NFGAFS317 in stress granules formation is 
yet to be validated, the middle pathway is shown by gray dashed lines, emphasizing that this 
pathway is speculative.
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Table 2
Statistics of MicroED data collection and atomic refinement.
SWGMMGMLASQ
(EMD-7467, 6CFH)
NFGEFS
(EMD-8857, 5WKB)
NFGpTFS
(EMD-7466, 6CF4)
Data Collection
Space group P1 P21212 P212121
Cell dimensions
  a, b, c (A°) 8.56, 9.60, 39.97 42.77, 17.42, 4.90 23.65, 4.72, 30.06
  α, β, γ (°) 97.2, 92.9, 105.9 90, 90, 90 90, 90, 90
Resolution (Å) 1.50 (1.55–1.50)a 1.00 (1.03–1.00) 0.75 (0.77–0.75)
Rmerge (%) 20.8 (85.5)b 28.3 (99.3)c 17.2 (66.1)
I/σ(I) 3.3 (0.7) 4.6 (1.1) 3.9 (1.3)
CC1/2 98.7 (72.0) 99.2 (36.0) 98.9(59.9)
Completeness (%) 93.5 (89.4) 88.7 (78.0) 86.6(87.2)
Redundancy 4.2 (2.4) 9.5 (4.8) 3.8 (4.0)
Refinement
Resolution (Å) 13.17–1.50 21.39–1.00 7.65–0.75
No. reflections 1,819 1,801 4,178
Rwork/Rfree 28.0/31.3 22.0/27.0 23.2/25.1
No. atoms
  Protein 162 90 93
  Water 0 2 1
B factors
  Protein atoms 18.1 5.3 19.6
  Water - 25.3 3.1
R.m.s. deviations
  Bond lengths (Å) 0.007 0.016 0.021
  Bond angles (°) 0.91 1.09 2.04
a
Highest resolution shell shown in parenthesis.
b
Data are from 7 crystals.
c
Data are from 4 crystals.
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